Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velneperit for weight loss in obesity
NCT00748605Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2007
- Primary completion
- Nov 2008
- Countries
- 1
- Sponsor
- Shionogi & Co., Ltd.
- Drugs
- velneperit
- Conditions
- obesity
01
Overview
Phase 2, randomised, double-blind trial of velneperit in obesity, sponsored by Shionogi & Co., Ltd. Started Jun 2007; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Results
Primary endpoints met
04
Registry description
1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800 kcal deficit reduced calorie diet (RCD) compared with placebo in medically stable and otherwise healthy obese male and female subjects 2. To evaluate the safety and tolerability of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week LCD with or without S-2367 followed by 54 weeks on a RCD compared with placebo in medically stable and…
Beyond the preview
Go deeper on NCT00748605.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00748605.